Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic

We carried out a critical appraisal of the literature to assess whether Janus kinase inhibitors are an effective treatment for palmoplantar pustulosis, a rare and debilitating form of psoraisis. Our appraisal identified case reports and case series of 16 patients who have been treated to good effect with tofacitinib, indicating this may be a promising therapeutic option. However, routine use of janus kinase inhibitors cannot be recommended outside the context of a clinical trial given the current low-quality of evidence available and the uncertain safety profile of Janus kinase inhibitors.

Automated summary

We conducted a critical assessment of the literature and found that Janus kinase inhibitors, specifically tofacitinib, showed promising therapeutic effects for palmoplantar pustulosis, based on case reports and case series. However, due to the limited evidence and uncertain safety profile, the routine use of Janus kinase inhibitors for this condition is not recommended outside of clinical trials.